Valganciclovir + Ganciclovir

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus Retinitis

Conditions

Cytomegalovirus Retinitis, HIV Infections

Trial Timeline

Jan 1, 1997 → Dec 1, 2002

NCT ID

NCT00002377

About Valganciclovir + Ganciclovir

Valganciclovir + Ganciclovir is a phase 3 stage product being developed by Roche for Cytomegalovirus Retinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00002377. Target conditions include Cytomegalovirus Retinitis, HIV Infections.

What happened to similar drugs?

8 of 20 similar drugs in Cytomegalovirus Retinitis were approved

Approved (8) Terminated (2) Active (10)

✅LetermovirMerckApproved

✅Single arm (ganciclovir and valganciclovir)RocheApproved

✅Ganciclovir + valganciclovir [Valcyte]RocheApproved

✅ValganciclovirRocheApproved

✅valganciclovir [Valcyte]RocheApproved

✅Valganciclovir + CMV hyperimmune globulin + ValganciclovirCSLApproved

✅CytogamKamadaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01185223	Phase 3	Terminated	Sep 1, 2010	—	Allogeneic Stem Cell Transplantation
NCT00002377	Phase 3	Completed	Jan 1, 1997	Dec 1, 2002	Cytomegalovirus Retinitis

Competing Products

20 competing products in Cytomegalovirus Retinitis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40